TY - JOUR
T1 - Molecular Susceptibility and Treatment Challenges in Melanoma
AU - Kolathur, Kiran Kumar
AU - Nag, Radhakanta
AU - Shenoy, Prathvi V.
AU - Malik, Yagya
AU - Varanasi, Sai Manasa
AU - Angom, Ramcharan Singh
AU - Mukhopadhyay, Debabrata
N1 - Publisher Copyright:
© 2024 by the authors.
PY - 2024/8
Y1 - 2024/8
N2 - Melanoma is the most aggressive subtype of cancer, with a higher propensity to spread compared to most solid tumors. The application of OMICS approaches has revolutionized the field of melanoma research by providing comprehensive insights into the molecular alterations and biological processes underlying melanoma development and progression. This review aims to offer an overview of melanoma biology, covering its transition from primary to malignant melanoma, as well as the key genes and pathways involved in the initiation and progression of this disease. Utilizing online databases, we extensively explored the general expression profile of genes, identified the most frequently altered genes and gene mutations, and examined genetic alterations responsible for drug resistance. Additionally, we studied the mechanisms responsible for immune checkpoint inhibitor resistance in melanoma.
AB - Melanoma is the most aggressive subtype of cancer, with a higher propensity to spread compared to most solid tumors. The application of OMICS approaches has revolutionized the field of melanoma research by providing comprehensive insights into the molecular alterations and biological processes underlying melanoma development and progression. This review aims to offer an overview of melanoma biology, covering its transition from primary to malignant melanoma, as well as the key genes and pathways involved in the initiation and progression of this disease. Utilizing online databases, we extensively explored the general expression profile of genes, identified the most frequently altered genes and gene mutations, and examined genetic alterations responsible for drug resistance. Additionally, we studied the mechanisms responsible for immune checkpoint inhibitor resistance in melanoma.
UR - http://www.scopus.com/inward/record.url?scp=85202464917&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85202464917&partnerID=8YFLogxK
U2 - 10.3390/cells13161383
DO - 10.3390/cells13161383
M3 - Review article
C2 - 39195270
AN - SCOPUS:85202464917
SN - 2073-4409
VL - 13
JO - Cells
JF - Cells
IS - 16
M1 - 1383
ER -